-
PROVIDERS
TEMPUS PUBLICATIONS
Browse our latest selection of abstracts, manuscripts, and presentations.
-
LIFE SCIENCES
NEW PRODUCT
xF Monitor: Tumor uninformed treatment response monitoring (TRM) assay for RUO ctDNA detection and quantification
- PATIENTS
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
Content
-
ArticlesQ&A: Impact of multimodal data in translational science
Analysis of real-world data (RWD) streamlines translational research and enables providers and researchers to provide precision medicine to patients at scale. -
Case StudiesTriHealth achieved 9X annual enrollment increase with Tempus TIME
Discover how a multi-location hospital network leveraged TIME to dramatically increase clinical trial enrollment across their oncology portfolio. -
ArticlesQ&A: Grow your clinical trial portfolio and increase enrollment with the TIME clinical trial network
Jason Claes, Clinical Research Manager at TriHealth, shares his perspective on optimizing TIME to increase clinical trial enrollment. -
WebinarsImpact of multimodal data in translational science
In this panel session we spoke to Translational Scientists who have been utilizing multi-modal insights in their daily work and discussed what new information can come to light by utilizing these tools. -
ArticlesFive key learnings regarding clinical and research applications of liquid biopsy
Scientific and medical leaders from Tempus discuss the evolution of liquid biopsy in clinical practice and development. -
Webinars
An analysis on the utility of liquid biopsy (LBx) throughout clinical development
Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy. -
ArticlesThe value of RNA sequencing in drug discovery
Learn the value of RNA Sequencing in identifying altered expression programs in tumors that are measurable by RNA-Seq but not DNA-Seq. -
ArticlesAccelerating patient enrollment with just-in-time trials: TriHealth on the TIME program
The traditional model of activating clinical trials is widely acknowledged as inefficient. The process of establishing a clinical site, negotiating partnerships between sites and sponsors, then attempting to recruit eligible patients in nearby areas can take many months, and it becomes a burden to trial site staff, sponsors, and patients. -
Articles5 things to know when navigating clinical development and regulatory pathways for CDx
Scientific and regulatory leaders from Tempus discuss how Tempus’ platform can enhance clinical development for CDx. -
ArticlesQ&A: Using liquid biopsies to build CDx in pancreatic cancer with Actuate Therapeutics
Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer. -
VideosAACR GSK Product Theater
The Tempus Spotlight Theater this year was on “Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development” and was a fireside chat between Kate Sasser, Chief Scientific Officer at Tempus and Anne-Marie Martin, SVP Global Head in the Experimental Medicine Unit at GSK. -
WebinarsAccelerate clinical trial enrollment and site activation
Learn how TriHealth uses the TIME network to identify trial subjects and rapidly activate new clinical trials within its oncology portfolio within an average of ~10 business days. -
WebinarsTempus’ FDA approval and insights on the use of companion diagnostics in clinical development
Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel. -
Case StudiesUsing TIME to accelerate trial enrollment for Aadi Bioscience
The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days. -
Webinars
NGS in advanced breast cancer: exploring recent clinical advancements
Learn more about breast cancer management with NGS. We explore the potential utility of complementary solid tumor and liquid biopsy testing in informing treatment decisions, as well as patient management strategies in the post CDK4/6 inhibitor therapy setting. -
ArticlesUsing multimodal real-world data for decision-making
Learn more about Gilead Sciences’ efforts to drive biomarker innovations and assemble their organization for integrated, data-driven research. -
WebinarsIncreasing PTS using multimodal data
Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies. -
ArticlesQ&A: Using RWE for CDx and drug development
Leaders from Kronos Bio discuss how they use RWD from heterogeneous sources to strengthen companion diagnostic and drug development strategies. -
Case StudiesUltra-rapid site activation and subject consent in PARPi Study using Tempus TIME Program
The TIME program enabled activation of a new clinical trial site within 4 business days for a PARPi study. Read on to learn how the patient was able to dose within 10 days of being identified as a match for the trial. -
ArticlesQ&A: De-risking clinical trials with real-world data
Iker Huerga, SVP, Life Sciences Strategy and RWD at Tempus, discusses how heterogeneous data sources can strengthen clinical trial planning and execution to de-risk research.